Terms: = Thyroid cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
2645 results:
1. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic value of high-frequency ultrasound combined with fine needle aspiration cytology and braf gene for papillary thyroid microcarcinoma.
Li C; Zhao X; Zhao J; Zhao J; An L; Wu G
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):187-191. PubMed ID: 38650135
[TBL] [Abstract] [Full Text] [Related]
3. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring braf
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
4. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
5. Genetic alterations and allele frequency of braf V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study.
Huang J; Wang J; Xv J; Wang J; Wang G; Zhao Y
Clin Exp Med; 2024 Apr; 24(1):76. PubMed ID: 38607456
[TBL] [Abstract] [Full Text] [Related]
6. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract] [Full Text] [Related]
7. A machine learning approach for predicting radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma undergoing tomotherapy.
Quan KR; Lin WR; Hong JB; Lin YH; Chen KQ; Chen JH; Cheng PJ
Sci Rep; 2024 Apr; 14(1):8436. PubMed ID: 38600141
[TBL] [Abstract] [Full Text] [Related]
8. braf and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract] [Full Text] [Related]
9. Correlation Between the Clinicopathological Features of Papillary thyroid Carcinoma Complicated with Hashimoto's thyroiditis, braf V600E Gene Mutation, and RET Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological Features and Molecular Signatures of Lateral Neck Lymph Node Metastasis in Papillary thyroid Microcarcinoma.
Lim J; Lee HS; Heo JH; Song YS
Endocrinol Metab (Seoul); 2024 Apr; 39(2):324-333. PubMed ID: 38572535
[TBL] [Abstract] [Full Text] [Related]
11. braf
Zhao H; Liu CH; Lu Y; Liu SZ; Yeerkenbieke P; Cao Y; Xia Y; Gao LY; Liu YW; Liu ZW; Chen SG; Liang ZY; Li XY
Oral Oncol; 2024 May; 152():106755. PubMed ID: 38547780
[TBL] [Abstract] [Full Text] [Related]
12. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated thyroid Carcinomas.
Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
[TBL] [Abstract] [Full Text] [Related]
13. RAF inhibitor re-challenge therapy in braf-aberrant pan-cancers: the RE-RAFFLE study.
Nelson BE; Roszik J; Ahmed J; Barretto CMN; Nardo M; Campbell E; Johnson AM; Piha-Paul SA; Oliva ICG; Weathers SP; Cabanillas M; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer; 2024 Mar; 23(1):64. PubMed ID: 38532456
[TBL] [Abstract] [Full Text] [Related]
14. Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.
Ghossein R; Katabi N; Dogan S; Shaha AR; Tuttle RM; Fagin JA; Ganly I; Xu B
Histopathology; 2024 Jun; 84(7):1130-1138. PubMed ID: 38528726
[TBL] [Abstract] [Full Text] [Related]
15. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
[TBL] [Abstract] [Full Text] [Related]
16. Advances in targeted therapy and biomarker research in thyroid cancer.
Guo M; Sun Y; Wei Y; Xu J; Zhang C
Front Endocrinol (Lausanne); 2024; 15():1372553. PubMed ID: 38501105
[TBL] [Abstract] [Full Text] [Related]
17. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract] [Full Text] [Related]
18. Progress in long non-coding RNAs as prognostic factors of papillary thyroid carcinoma.
Zhu HN; Song DL; Zhang SN; Zheng ZJ; Chen XY; Jin X
Pathol Res Pract; 2024 Apr; 256():155230. PubMed ID: 38461693
[TBL] [Abstract] [Full Text] [Related]
19. Correlation between genetic alterations and clinicopathological features of papillary thyroid carcinomas.
Shang S; Yang H; Chen M; Wu J; Shi X; Li X; Feng N; Zheng Z; Liu H; Zhang Y
J Int Med Res; 2024 Mar; 52(3):3000605241233166. PubMed ID: 38456650
[TBL] [Abstract] [Full Text] [Related]
20. [Stratified application of gene expression in diagnosis of thyroid nodules].
Guan WY; Zheng JY; Nie L; Wu HY
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):264-268. PubMed ID: 38433054
[No Abstract] [Full Text] [Related]
[Next]